Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: jrhana who wrote (9545)	11/23/2003 12:44:26 PM
From: scaram(o)uche	Respond to of 52153

>> I think we are years away from another biotech stock boom << Do you mean apart from the one that we're in? Biotech's version of PDE5 inhibitor was approved by FDA on Friday. It should steal the show, and the stage has universal appeal. Lilly also bought AMEV on Friday, for a nice premium and a 550% run in eight months. Not too many of my stocks are far from a 52 week high. So, what's wrong with the "boom" that is today's?

To: jrhana who wrote (9545)	11/24/2003 4:16:41 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

HDL gene therapy story At this point there is still profound wariness by investors on any sort of gene therapy. Gene therapy for a chronic disease like atherosclerosis (where there are alternative treatments) is even further off, as it will need to meet very strict safety standards. My guess is that we will see it first in more severe diseases like hemophilia or cystic fibrosis. A therapy like you pointed to is still at least a decade away from the market in my view. A nearer-term play on ApoE (minus the gene therapy part) is likely ESPR, which was discussed extensively on this thread a few weeks ago. Peter